Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D. will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 1:30 p.m. ET.

According to the company, a live webcast and archived replay will be available via the Unicycive investor website under Events and Presentations. Investors seeking 1x1 meetings should contact their Guggenheim conference representative.

News Market Reaction – UNCY

-5.92%

7 alerts

-5.92% Session close to close

-4.1% Trough in 1 hr 12 min

$141.95M Market Cap

0.3x Rel. Volume

In the Feb 4 session, UNCY declined 5.92%, reflecting a notable negative market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.9% in the session following this news. A negative reaction despite a routine conf...

Analysis

The stock moved -5.9% in the session following this news. A negative reaction despite a routine conference announcement would fit UNCY’s pattern of inconsistent responses to generally neutral or positive news. Recent history shows sizeable swings around regulatory updates and investor events, reflecting sensitivity to positioning and liquidity rather than news quality alone. Past equity issuance expanded the float, which can amplify downside pressure when sentiment cools between substantive clinical or regulatory milestones.

Key Figures

Fireside chat time: 1:30 p.m. ET

1 metrics

Fireside chat time 1:30 p.m. ET Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 29	Regulatory milestone	Positive	-5.0%	FDA acceptance of resubmitted NDA for OLC with set PDUFA date.
Dec 29	Regulatory update	Positive	-2.3%	Resubmission of NDA for OLC and expectations for new PDUFA timing.
Nov 25	Investor conferences	Neutral	+3.6%	Announcement of December investor events and webcast access.
Nov 12	Earnings and update	Positive	+7.3%	Q3 2025 results, OLC progress, and cash runway into 2027.
Nov 03	Investor conference	Neutral	-6.5%	Planned fireside chat at Guggenheim healthcare innovation conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News often shows divergence between headline tone and price: 4 of the last 5 events saw price reactions that did not clearly align with generally positive or neutral disclosures, including regulatory milestones and conference participation.

Recent Company History

Over the last few months, UNCY has focused on advancing oxylanthanum carbonate (OLC) and engaging investors. Regulatory milestones included NDA resubmission on Dec 29, 2025 and FDA acceptance with a Jun 27, 2026 PDUFA date on Jan 29, 2026, both followed by modest declines. An earnings update on Nov 12, 2025 highlighting cash runway into 2027 coincided with a 7.31% gain. Prior Guggenheim and other conference appearances produced mixed reactions, showing that investor events can move the stock but not consistently in one direction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Guggenheim conference representative.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:

Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When will Unicycive (UNCY) present at the Guggenheim Emerging Outlook: Biotech Summit?

The fireside chat is scheduled for Wednesday, February 11, 2026 at 1:30 p.m. ET, sharp. According to Unicycive, the session will be livestreamed and archived; investors can access the webcast via the company's Investors Events and Presentations page after the event.

How can investors watch the UNCY fireside chat webcast and replay?

Investors can view a live webcast and later archived replay on Unicycive's investor website Events and Presentations section. According to Unicycive, the webcast link will be posted under Investors: Events and Presentations and a replay will be available after the session.

How do I schedule a 1x1 meeting with Unicycive management at the Guggenheim summit (UNCY)?

To schedule a 1x1 meeting, contact your Guggenheim conference representative to request time with Unicycive management. According to Unicycive, management is coordinating meetings through Guggenheim and investors should arrange meetings through their conference contact in advance.

Will CEO Shalabh Gupta discuss Unicycive's clinical programs during the February 11, 2026 UNCY fireside chat?

Shalabh Gupta will participate in a fireside chat but specific presentation topics were not detailed in the announcement. According to Unicycive, attendees are encouraged to join the webcast or request 1x1 meetings for more detailed clinical-program discussions.